Skyrizi vs Tremfya
Risankizumab vs Guselkumab · Comparison Guide
Quick Comparison
| Feature | Skyrizi | Tremfya |
|---|---|---|
| Generic Name | Risankizumab | Guselkumab |
| Manufacturer | AbbVie | Janssen |
| Drug Class | IL-23 Inhibitor | IL-23 Inhibitor |
| Shared Conditions | Plaque Psoriasis, Psoriatic Arthritis | |
Key Differences: Skyrizi vs Tremfya
Both target IL-23 (p19 subunit) and are approved for psoriasis and PsA. Skyrizi is dosed every 12 weeks (4x/year); Tremfya is dosed every 8 weeks (6–7x/year). Head-to-head data is limited. Both demonstrate high PASI 90/100 clearance rates. Skyrizi is also approved for Crohn's disease; Tremfya is not. Copay programs for both are strong through AbbVie and Janssen respectively.
💊 Skyrizi (Risankizumab)
- Class: IL-23 Inhibitor
- Manufacturer: AbbVie
- Full Skyrizi information →
💊 Tremfya (Guselkumab)
- Class: IL-23 Inhibitor
- Manufacturer: Janssen
- Full Tremfya information →
Both target IL-23 (p19 subunit) and are approved for psoriasis and PsA. Skyrizi is dosed every 12 weeks (4x/year); Tremfya is dosed every 8 weeks (6–7x/year). Head-to-head data is limited. Both demonstrate high PASI 90/100 clearance rates. Skyrizi is also approved for Crohn's disease; Tremfya is not. Copay programs for both are strong through AbbVie and Janssen respectively.
Neither Skyrizi nor Tremfya is universally better — the right choice depends on your specific condition, disease severity, insurance formulary, and health history. Your prescriber will determine which is most appropriate based on your clinical situation. BiologicHealthPlus carries both and can help you compare your coverage and costs for either medication.
Switching between biologics is common. Your prescriber will evaluate your current treatment response and determine if a switch is appropriate. BiologicHealthPlus can coordinate the transition including prior authorization for your new medication.
Both Skyrizi and Tremfya are covered by most commercial insurance plans, Medicare Part D, and Medicaid with prior authorization. BiologicHealthPlus handles insurance verification and prior authorization for both medications at no charge. Most insured patients pay $0–$35/month through manufacturer copay programs.
Skyrizi and Tremfya both have high cash list prices ($4,000–$9,000/month range) but most commercially insured patients pay $0–$35/month through manufacturer savings programs. BiologicHealthPlus automatically enrolls every patient in all available savings programs at no charge.
✅ BiologicHealthPlus Carries Both Skyrizi and Tremfya
We handle insurance verification, prior authorization, copay enrollment, and free cold-chain delivery for both medications. Contact us and we'll help you understand your options and costs.
Medical Disclaimer: This comparison is for educational purposes only. The choice between Skyrizi and Tremfya should be made by your healthcare provider based on your specific medical history, disease severity, and individual circumstances. Last updated: July 2026.